Myriad Genetics Receives the Charles R. Smart Visionary Award From the American Cancer Society(R)

| Source: Myriad Genetics, Inc.

SALT LAKE CITY, June 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics announced today that the Company is the honorable recipient of the 2012 Charles R. Smart Visionary Award from the American Cancer Society's Salt Lake City office, a part of the Great West Division. This award is presented annually at the Society's Legacy & Leadership event to recognize organizations that have made extraordinary efforts in the fight against cancer.

Myriad and its employees are dedicated to saving lives and improving the quality of life of patients with cancer. In addition to its life-saving molecular diagnostic tests, Myriad is a local community leader with the American Cancer Society in the fight against cancer. The Company and its employees have played an important role in events to benefit the American Cancer Society including the Hope Gala, Making Strides Against Breast Cancer and Relay for Life.  

"We are deeply honored to receive the Charles R. Smart Visionary award," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics. "Myriad and the American Cancer Society share the goal of improving the quality of life for patients with cancer. Everyday our activities are guided by this mission and therefore we have been pleased to offer our financial support, leadership involvement and volunteer participation to this cause."

The late Dr. Charles R. Smart, a lifelong resident of Utah, was a pioneer in the study of cancer. Dr. Smart spent more than 35 years focused on establishing computerized cancer research and was the founder of the Utah Cancer Registry, a population based registry that has been doing systematic cancer surveillance in the state since 1966.  

About Myriad Genetics

Myriad Genetics, Inc., an internationally recognized leader in molecular diagnostics, is dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's strategic directives under the caption "About Myriad Genetics". These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; the risk that we may be unable to expand into new markets outside of the United States; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services and any future products are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of healthcare payment systems; risks related to our ability to obtain new corporate collaborations and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we acquire; the development of competing tests and services; the risk that we or our licensors may be unable to protect the proprietary technologies underlying our tests; the risk of patent-infringement and invalidity claims or challenges of our patents; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Rebecca Chambers
Director, Investor Relations and Corporate Communications
(801) 584-1143